95 related articles for article (PubMed ID: 26667974)
1. Chemotherapy: NAPOLI-1: winning scoop for metastatic pancreatic cancer.
Hutchinson L
Nat Rev Clin Oncol; 2016 Jan; 13(1):2-3. PubMed ID: 26667974
[No Abstract] [Full Text] [Related]
2. Nanoliposomal irinotecan in metastatic pancreatic cancer.
Milosevic I; Drysdale H; Goldacre B;
Lancet; 2016 May; 387(10032):1997. PubMed ID: 27203772
[No Abstract] [Full Text] [Related]
3. Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply.
Chen LT; Wang-Gillam A; Von Hoff DD; Bayever E; Belanger B
Lancet; 2016 May; 387(10032):1997. PubMed ID: 27203770
[No Abstract] [Full Text] [Related]
4. Gemcitabine-resistant pancreatic cancer: a second-line option.
Oettle H; Lehmann T
Lancet; 2016 Feb; 387(10018):507-508. PubMed ID: 26616909
[No Abstract] [Full Text] [Related]
5. Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals.
Bates SE; Fojo T
Nat Rev Clin Oncol; 2016 Apr; 13(4):205-6. PubMed ID: 26902963
[No Abstract] [Full Text] [Related]
6. Predicting a response to FOLFIRINOX in pancreatic cancer.
Nipp RD; Ryan DP
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26025325
[No Abstract] [Full Text] [Related]
7. Pancreatic ductal adenocarcinoma: metastatic disease.
Muñoz Martín AJ; Adeva J; Martínez-Galán J; Reina JJ; Hidalgo M
Clin Transl Oncol; 2017 Dec; 19(12):1423-1429. PubMed ID: 28623515
[TBL] [Abstract][Full Text] [Related]
8. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Sclafani F; Iyer R; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
[TBL] [Abstract][Full Text] [Related]
9. Complete pathological response after chemotherapy alone in a patient with pancreatic adenocarcinoma.
Carbonell S; Espinosa J; Zarco A; de-Madaria E; de la Hoz J; Yuste A; Payá A; Lluís F
Pancreas; 2012 May; 41(4):657-9. PubMed ID: 22504386
[No Abstract] [Full Text] [Related]
10. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
[TBL] [Abstract][Full Text] [Related]
11. Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability.
Mondo EL; Noel MS; Katz AW; Schoeniger LO; Hezel AF
J Clin Oncol; 2013 Jan; 31(3):e37-9. PubMed ID: 23233707
[No Abstract] [Full Text] [Related]
12. Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma.
Marsh Rde W; George T
Curr Gastroenterol Rep; 2006 Apr; 8(2):111-20. PubMed ID: 16533473
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
Tinchon C; Hubmann E; Pichler A; Keil F; Pichler M; Rabl H; Uggowitzer M; Jilek K; Leitner G; Bauernhofer T
Acta Oncol; 2013 Aug; 52(6):1231-3. PubMed ID: 23445338
[No Abstract] [Full Text] [Related]
14. Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma.
Bisht S; Brossart P; Feldmann G
Oncol Res Treat; 2018; 41(10):590-594. PubMed ID: 30286472
[TBL] [Abstract][Full Text] [Related]
15. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.
Valeri S; Borzomati D; Nappo G; Perrone G; Santini D; Coppola R
Pancreatology; 2014; 14(5):425-30. PubMed ID: 25278312
[TBL] [Abstract][Full Text] [Related]
16. Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course.
Boeck S; Mehraein Y; Ormanns S; Kruger S; Westphalen CB; Haas M; Jung A; Kirchner T; Heinemann V
Ann Oncol; 2017 Feb; 28(2):438-439. PubMed ID: 27803004
[No Abstract] [Full Text] [Related]
17. [nab-Paclitaxel as new therapeutic option for pancreatic cancer].
Michl P
Z Gastroenterol; 2013 Nov; 51(11):1329-30. PubMed ID: 24243574
[No Abstract] [Full Text] [Related]
18. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure.
Chauhan VP; Boucher Y; Ferrone CR; Roberge S; Martin JD; Stylianopoulos T; Bardeesy N; DePinho RA; Padera TP; Munn LL; Jain RK
Cancer Cell; 2014 Jul; 26(1):14-5. PubMed ID: 25026209
[No Abstract] [Full Text] [Related]
19. Response to Chauhan et Al.: interstitial pressure and vascular collapse in pancreas cancer-fluids and solids, measurement and meaning.
DelGiorno KE; Carlson MA; Osgood R; Provenzano PP; Brockenbough JS; Thompson CB; Shepard HM; Frost GI; Potter JD; Hingorani SR
Cancer Cell; 2014 Jul; 26(1):16-7. PubMed ID: 25026210
[No Abstract] [Full Text] [Related]
20. A gut response: Modulating chemotherapy efficacy with microbial metabolites.
Bauer KC; Greten TF
Immunity; 2023 Apr; 56(4):750-752. PubMed ID: 37044066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
